Drug Name:
REGN2810*
Drug Description:
PD-1 Antibody
Target Condition:
Cutaneous squamous cell carcinoma, basal cell carcinoma
Rank:
50
Phase:
Phase 2
Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases.
Read onOur robust research and development engine allows us to discover therapies that could have a profound impact on patient health.
Read onOur goal is to address serious medical conditions, across multiple and diverse therapeutic areas. Our FDA-approved medicines are only the beginning of our long-term commitment to solve the human body's most complex mysteries.
Read onIn addition to our work to invent new and needed medicines, we are focused on improving our world and operating with the highest standards of integrity. We are proud not only of what we do, but how we do it.
Read on